Retatrutide TRIUMPH-1 Results: 28.3% Weight Loss in 2,339 Patients — Full Breakdown

What's New: TRIUMPH-1 Announced (May 21, 2026)

• Results announced: May 21, 2026 — Eli Lilly press release
• Trial status: ✅ Complete — all primary and key secondary endpoints met
• Key result: 28.3% average weight loss at 80 weeks (12mg dose, N=2,339)
• NDA impact: Eli Lilly now has the primary efficacy dataset required for Q4 2026 NDA filing
• Next trial to watch: TRIUMPH-2 (diabetes) — expected Q3–Q4 2026‍

Introduction

On May 21, 2026, Eli Lilly announced the topline results of TRIUMPH-1 — the pivotal Phase 3 trial that determines whether retatrutide will receive FDA approval for obesity treatment. The results were unambiguous: 28.3% average weight loss at 80 weeks in 2,339 adults without diabetes, meeting all primary and key secondary endpoints.

This is the trial the FDA has been waiting for. TRIUMPH-4 (December 2025, 28.7% weight loss) established proof of concept in a specific population. TRIUMPH-1, with its larger and more general population, provides the pivotal efficacy evidence required for a New Drug Application. Eli Lilly now has what it needs to file.

This article breaks down every data point from TRIUMPH-1, compares it to TRIUMPH-4, explains what the 104-week extension data means, and outlines the direct impact on the FDA approval timeline.

TRIUMPH-1 Trial Overview

TRIUMPH-1 is the largest and most important trial in Eli Lilly's TRIUMPH Phase 3 program. It was designed specifically to evaluate retatrutide in the broadest obesity population — adults without diabetes — and to serve as the primary evidence base for FDA approval.

Source: Eli Lilly press release, May 21, 2026. Full peer-reviewed publication pending.

Key Results: What the Data Shows

Primary Endpoint: Weight Loss

The 12mg retatrutide group achieved 28.3% average weight loss at 80 weeks — compared to approximately 2% in the placebo group. For a 250-pound person, this translates to roughly 71 pounds lost.

This result is clinically significant for three reasons. First, 28.3% approaches the weight loss seen with bariatric surgery (25–35%), without surgical risks. Second, it is consistent with TRIUMPH-4 (28.7%), confirming retatrutide produces reliable results across different populations. Third, it far exceeds all currently approved obesity medications.

Responder Rates: The Most Important Numbers

Average weight loss tells part of the story. Responder rates reveal how consistently retatrutide works across patients — and the TRIUMPH-1 numbers are remarkable.

The 45.3% figure — nearly half of all patients losing ≥30% of their body weight — is unprecedented in obesity pharmacotherapy. No approved medication comes close to this responder rate at this threshold.

BMI Outcomes: Crossing the Obesity Threshold

65.3% of patients on the 12mg dose dropped their BMI below 30 — moving from the "obese" to the "overweight" or "normal" BMI category. This represents a clinically meaningful change in cardiovascular and metabolic risk. Semaglutide (Wegovy) achieves this in approximately 30% of patients. Retatrutide more than doubles that rate.

The 104-Week Extension: Weight Loss Doesn't Stop at 80 Weeks

TRIUMPH-1 included a prespecified 104-week extension in patients with BMI ≥35. At 104 weeks (2 years), patients in this subgroup reached 30.3% average weight loss — confirming that retatrutide doesn't plateau at the primary endpoint and continues to improve with extended treatment.

Safety Profile: Better Tolerability Than TRIUMPH-4

One of the most encouraging findings from TRIUMPH-1 is the discontinuation rate: 11.3%. This is substantially lower than TRIUMPH-4's 18.2%, and compares favorably to tirzepatide (Zepbound) at 14.9%.

Full side effect data from TRIUMPH-1 will be published in a peer-reviewed journal. Based on TRIUMPH-4 precedent and the mechanism of action, the side effect profile is expected to include nausea, diarrhea, vomiting, and dysesthesia. The lower discontinuation rate suggests these were more manageable in the TRIUMPH-1 population. For a complete overview of retatrutide side effects and management strategies, see our complete side effects guide.

TRIUMPH-1 vs TRIUMPH-4: How Do They Compare?

With two completed Phase 3 trials, the consistency of retatrutide's results across different populations is striking — and exactly what the FDA looks for.

The 0.4 percentage point difference in weight loss (28.7% vs 28.3%) is statistically negligible. What matters is that both trials, in different populations and different durations, produced nearly identical efficacy results.

Impact on FDA Approval Timeline

TRIUMPH-1 was the pivotal trial the FDA required before Eli Lilly could file a New Drug Application. With these results confirmed, the regulatory pathway is now clear.

Q4 2026 — NDA Submission: Eli Lilly confirmed on its Q1 2026 earnings call that NDA submission remains on track. TRIUMPH-1 data is the final major piece of the submission package.

Q1 2027 — FDA Filing Decision: The FDA has 60 days to review the submission for completeness. If accepted, they assign a PDUFA date.

Late 2027 — PDUFA Date: Based on historical obesity drug review times (4–10 months), FDA action is expected in late 2027.

Q1–Q2 2028 — Commercial Launch: If approved, 1–3 months post-approval for manufacturing and distribution preparation.

For the complete FDA approval process breakdown, see our comprehensive FDA approval timeline guide.

What TRIUMPH-1 Means for Patients

The Drug Works Consistently

TRIUMPH-4 was sometimes questioned as a result specific to an unusual population. TRIUMPH-1, with 2,339 general obesity patients, removes that doubt. Retatrutide produces 28%+ weight loss consistently across different populations.

Nearly Half of Patients Lose ≥30% of Body Weight

The 45.3% responder rate at ≥30% is the number that matters most for patients. For a 300-pound person, ≥30% means losing 90+ pounds — previously achievable only through bariatric surgery.

Better Tolerated Than TRIUMPH-4 Suggested

The 11.3% discontinuation rate is encouraging. TRIUMPH-4's 18.2% raised concerns about tolerability. TRIUMPH-1 suggests that in a general obesity population, most patients can complete the full treatment course.

Weight Loss Continues Beyond 80 Weeks

The 30.3% result at 104 weeks confirms that staying on retatrutide long-term continues to deliver results. Retatrutide is not a short-term solution — the longest-term patients see the best outcomes.

Approval Is Now Highly Likely

With TRIUMPH-1 meeting all primary and key secondary endpoints, the scientific case for FDA approval is strong. Barring unexpected safety findings in remaining trials, retatrutide approval in late 2027 is the most probable outcome.

For those who don't want to wait until 2028, tirzepatide (Zepbound) currently offers the best available alternative at 22.5% average weight loss. For a detailed comparison, see our retatrutide vs tirzepatide comparison.

Conclusion

TRIUMPH-1 is the trial that makes retatrutide's approval case. With 28.3% average weight loss in 2,339 adults, 45.3% achieving ≥30% loss, and a discontinuation rate of just 11.3% — this is the most comprehensive and compelling evidence yet that retatrutide will transform obesity treatment.

The 104-week extension data showing 30.3% weight loss puts retatrutide in bariatric surgery territory for extended users — a milestone no medication has reached before.

Eli Lilly now has what it needs. The NDA submission in Q4 2026 is on track. For a complete overview of the entire TRIUMPH program and what to expect next, see our comprehensive retatrutide guide.

Sources & References

• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Eli Lilly press release: TRIUMPH-4 Phase 3 trial results. December 2025.
• Jastreboff AM, et al. "Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine 2023;389:514-526
• ClinicalTrials.gov: TRIUMPH Phase 3 program trial registry entries
• Eli Lilly Q1 2026 earnings call: NDA submission timeline confirmation
• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021
• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022